CASE 3 APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO EVALUATE THE PROPOSED FORMULARY STATUS OF A NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL HEALTH PLAN
May 1, 2007, 00:00
10.1016/S1098-3015(10)69137-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)69137-1/fulltext
Title :
CASE 3 APPLICATION OF COST-EFFECTIVENESS ANALYSIS TO EVALUATE THE PROPOSED FORMULARY STATUS OF A NOVEL ANTIDIABETIC DRUG IN A U.S. COMMERCIAL HEALTH PLAN
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)69137-1&doi=10.1016/S1098-3015(10)69137-1
First page :
Section Title :
Open access? :
No
Section Order :
337